| Obligatory | Must not donate if:
a) Has ever been given human gonadotrophin of pituitary origin.
b) If donor knows that they have ever been treated with Metrodin HP®. |
| Discretionary | If treated exclusively with non-pituitary derived gonadotrophins, accept. |
| See if Relevant | Hormone Replacement and Sex Hormone Therapy
Prion Associated Diseases |
| Additional Information | The use of human gonadotrophin of pituitary origin (follicle-stimulating hormone (FSH) and luteinizing hormone (LH)) had stopped in the UK by 1986. The situation in other countries varied so specific dates cannot be given.
Donors who have undergone egg donation, egg collection for fertility preservation, and surgical sperm retrieval should be assessed regarding any hormone treatment they have received.
There is no evidence that transfer of tissues (eggs or embryos) between individuals might lead to the spread of vCJD.
Metrodin HP® was withdrawn by the Committee on Safety of Medicines in 2003 and following advice from the Medicines and Healthcare products Regulatory Agency the precautionary principle has been applied to withdraw donors who have been treated with this product. Donors treated for infertility after 2003 in the UK will not have been treated with this product. |
| Reason for Change | To update ‘Additional Information’ section by removing the section regarding a 12-week safeguarding time from treatment, and inclusion of additional information regarding any hormone treatment received.
Addition of link to ‘Hormone Replacement Therapy’ entry. |